VERVE-102 Gene Edit Lowers Cholesterol

Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after a single infusion by switching off the PCSK9 gene in liver cells. The Phase 1b clinical trial, involving 35 adults with high cholesterol or premature coronary artery disease, showed LDL cholesterol reductions of up to 62% and PCSK9 protein reductions of up to 88% at the highest dose, with effects lasting up to 18 months. Researchers from University College London, University College London Hospitals NHS Foundation Trust, and United Kingdom — Barts Health NHS Trust>>> contributed to the study, which was published in the The New England Journal of Medicine. The therapy, led by cardiologist Sekar Kathiresan>>>, uses base editing technology and has shown no serious side effects related to the highest dose. The United States — Food and Drug Administration>>> has granted Fast Track designation to VERVE-102. While preliminary, these findings suggest a potential 'one-and-done' treatment for high cholesterol, which could revolutionize cardiovascular disease prevention and management, addressing issues of medication adherence with current treatments like statins and injectable PCSK9 inhibitors. Larger Phase 2 trials are planned for late 2026 to confirm long-term safety and effectiveness.